Skip to main content
Premium Trial:

Request an Annual Quote

Dako, Pfizer Reach Companion Dx Deal

NEW YORK (GenomeWeb News) – Agilent Technologies company Dako today announced a companion diagnostic agreement with Pfizer.

The deal establishes a legal framework for the two firms to carry out R&D and commercialization work as well as advisory services, Dako said.

"This partnership with Dako will support Pfizer's companion diagnostics efforts, an important component of our growing precision medicine capabilities," John Hubbard, senior vice president of Development Operations at Pfizer, said in a statement. "Precision medicine R&D is designed to advance more targeted therapies for patients, improve efficacy, safety and success rates, and expedite development."

Financial and other terms of the alliance were not disclosed. Dako also did not provide specifics about drugs and disease areas of interest.

The deal is the second one covering the development of companion diagnostics forged by Dako since the start of the year, following a similar agreement with Eli Lilly announced last month. Agilent acquired Dako in June for $2.2 billion in a transaction that expands Agilent's footprint in the diagnostics space.

In addition to Pfizer and Eli Lilly, Dako has arrangements to develop companion diagnostics for Roche's Genentech and for Amgen.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more